BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 22068809)

  • 1. Effects of pioglitazone versus simvastatin on biomarkers of inflammation in patients on high cardiovascular risk.
    Hanefeld M; Schaper F; Appelt D; Fuchs W
    Horm Metab Res; 2011 Dec; 43(13):980-3. PubMed ID: 22068809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
    Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
    J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
    Honda H; Qureshi AR; Heimbürger O; Barany P; Wang K; Pecoits-Filho R; Stenvinkel P; Lindholm B
    Am J Kidney Dis; 2006 Jan; 47(1):139-48. PubMed ID: 16377395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
    Lazich I; Sarafidis P; de Guzman E; Patel A; Oliva R; Bakris G
    Diabetes Obes Metab; 2012 Feb; 14(2):181-6. PubMed ID: 21955403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alanine aminotransferase and high sensitivity C-reactive protein: correlates of cardiovascular risk factors in youth.
    Oliveira AC; Oliveira AM; Almeida MS; Silva AM; Adan L; Ladeia AM
    J Pediatr; 2008 Mar; 152(3):337-42. PubMed ID: 18280837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients.
    Verrijken A; Francque S; Mertens I; Talloen M; Peiffer F; Van Gaal L
    Int J Obes (Lond); 2010 May; 34(5):899-907. PubMed ID: 20142825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-18 is involved in vascular injury in end-stage renal disease patients.
    Porazko T; Kúzniar J; Kusztal M; Kúzniar TJ; Weyde W; Kuriata-Kordek M; Klinger M
    Nephrol Dial Transplant; 2009 Feb; 24(2):589-96. PubMed ID: 18775894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-sensitivity C-reactive protein: a novel cardiovascular risk predictor in type 2 diabetics with normal lipid profile.
    Asegaonkar SB; Marathe A; Tekade ML; Cherekar L; Bavikar J; Bardapurkar J; Ajay R
    J Diabetes Complications; 2011; 25(6):368-70. PubMed ID: 22055258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis.
    Dessein PH; Norton GR; Woodiwiss AJ; Joffe BI; Solomon A
    J Rheumatol; 2007 Apr; 34(4):681-8. PubMed ID: 17299845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein.
    Guldiken S; Demir M; Arikan E; Turgut B; Azcan S; Gerenli M; Tugrul A
    Thromb Res; 2007; 119(1):79-84. PubMed ID: 16476470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients.
    Pfützner A; Schöndorf T; Hanefeld M; Lübben G; Kann PH; Karagiannis E; Wilhelm B; Forst T
    Horm Metab Res; 2009 Mar; 41(3):202-6. PubMed ID: 19224430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of endogenous sex hormone with C-reactive protein levels in middle-aged and elderly men.
    Nakhai Pour HR; Grobbee DE; Muller M; van der Schouw YT
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):394-8. PubMed ID: 17302874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong suppression of high-sensitivity C-reactive protein level and its mediated pro-atherosclerotic effects with simvastatin: in vivo and in vitro studies.
    Yip HK; Sun CK; Chang LT; Wu CJ; Chua S; Fu M
    Int J Cardiol; 2007 Oct; 121(3):253-60. PubMed ID: 17196684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of inflammatory markers for the prediction of neointimal hyperplasia after drug-eluting stent implantation.
    Kang WC; Il Moon C; Lee K; Han SH; Suh SY; Moon J; Shin MS; Ahn T; Shin EK
    Coron Artery Dis; 2011 Dec; 22(8):526-32. PubMed ID: 21909023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.
    Mora S; Rifai N; Buring JE; Ridker PM
    Circulation; 2006 Aug; 114(5):381-7. PubMed ID: 16864722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients.
    Panichi V; Paoletti S; Mantuano E; Manca-Rizza G; Filippi C; Santi S; Taccola D; Donadio C; Tramonti G; Innocenti M; Casto G; Consani C; Sbragia G; Franzoni F; Galetta F; Panicucci E; Barsotti G
    Nephrol Dial Transplant; 2006 Feb; 21(2):337-44. PubMed ID: 16249194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
    Ridker PM; Hennekens CH; Buring JE; Rifai N
    N Engl J Med; 2000 Mar; 342(12):836-43. PubMed ID: 10733371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus.
    Hernandez TL; Capell WH; Wolfe P; Gerard LA; Eckel RH
    Am J Cardiol; 2006 Dec; 98(12):1656-9. PubMed ID: 17145229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.